Corvel Corp (CRVL) valuation
Corvel P/E ratio history
Corvel trades at 36.5 times its earnings over the last twelve months. At its last 10 fiscal year ends its P/E ranged from 21.5 (year to Mar 2020) to 61.2 (year to Mar 2025), with a median of 34.5.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Mar 31, 2026 | $54.65 | $2.14 | 25.5 |
| Mar 31, 2025 | $111.97 | $1.83 | 61.2 |
| Mar 31, 2024 | $87.65 | $1.47 | 59.8 |
| Mar 31, 2023 | $63.43 | $1.26 | 50.5 |
| Mar 31, 2022 | $56.15 | $1.22 | 46.2 |
| Mar 31, 2021 | $34.20 | $0.85 | 40.2 |
| Mar 31, 2020 | $18.17 | $0.85 | 21.5 |
| Mar 31, 2019 | $21.75 | $0.82 | 26.5 |
| Mar 31, 2018 | $16.85 | $0.62 | 27.0 |
| Mar 31, 2017 | $14.50 | $0.50 | 28.8 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Corvel valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| CorvelCRVL | $4.17B | 36.5 | — | 4.2 |
| Indivior PharmaceuticalsINDV | $4.17B | 9.9 | 7.9 | 3.0 |
| Edgewise TherapeuticsEWTX | $4.18B | — | — | — |
| Icu MedicalICUI | $4.09B | 137.6 | 17.8 | 1.9 |
| Adaptive BiotechnologiesADPT | $4.26B | — | — | 13.8 |
| IrhythmIRTC | $4.05B | — | 137.3 | 4.9 |
| Integer HoldingsITGR | $4.30B | 42.2 | 18.9 | 2.4 |
| Arcutis BiotherapeuticsARQT | $4.01B | 145.8 | 36.4 | 8.6 |
| LiquidiaLQDA | $4.01B | 32.2 | 21.4 | 8.9 |
| Peer median | 42.2 | 20.1 | 4.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CRVL financials · CRVL returns
No forecast, no recommendation. This page describes Corvel Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.